Bicycle therapeutics announces interim bt8009 phase i clinical trial results selected for an oral presentation at the 2022 aacr annual meeting

Cambridge, england & boston--(business wire)--bicycle therapeutics plc (nasdaq: bcyc), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (bicycle®) technology, today announced that interim phase i results from the phase i/ii trial of bt8009, a second-generation btc™ targeting nectin-4, has been selected for an oral presentation at the upcoming 2022 american association for cancer research annual meeting, being held april
BCYC Ratings Summary
BCYC Quant Ranking